A comparison of the effects of oral and transdermal estrogen replacement on insulin sensitivity in postmenopausal women

Journal of Clinical Endocrinology and Metabolism

Volumn 80, Issue 6, 1995, Pages 1783-1788

  O'Sullivan, Anthony J ^a   Ho, Ken K Y ^a  

^a ST VINCENT S HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

CONJUGATED ESTROGEN; ESTRADIOL; FATTY ACID; GLUCOSE; GROWTH HORMONE; HUMAN INSULIN; INSULIN; LUTEINIZING HORMONE; NEUTRAL INSULIN;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; ESTROGEN THERAPY; FATTY ACID BLOOD LEVEL; FEMALE; GLUCOSE BLOOD LEVEL; GROWTH HORMONE BLOOD LEVEL; HUMAN; HUMAN EXPERIMENT; INSULIN BLOOD LEVEL; INSULIN SENSITIVITY; LUTEINIZING HORMONE BLOOD LEVEL; ORAL DRUG ADMINISTRATION; ORAL GLUCOSE TOLERANCE TEST; POSTMENOPAUSE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; TRANSDERMAL DRUG ADMINISTRATION;

ADMINISTRATION, CUTANEOUS; ADMINISTRATION, ORAL; CROSS-OVER STUDIES; ESTRADIOL; ESTROGEN REPLACEMENT THERAPY; ESTROGENS; FATTY ACIDS, NONESTERIFIED; FEMALE; GLUCOSE CLAMP TECHNIQUE; GLUCOSE TOLERANCE TEST; GROWTH HORMONE; HUMANS; INSULIN; KINETICS; MIDDLE AGED; POSTMENOPAUSE; PROSPECTIVE STUDIES;

EID: 0029064538     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/jcem.80.6.7775623     Document Type: Article

References (36)

1. Welbom TA, Weame K. 1979 Coronary heart disease incidence and cardiovascular mortality in Busselton with reference to glucose and insulin concentrations. Diabetes Care. 2:154-160.
2. Zavaroni I, Bonora E, Pagliara M, et al. 1989 Risk factors for coronary artery disease in healthy persons with hyperinsulinemia and normal glucose tolerance. N Engl J Med. 320:702-706.
3. Stout RW. 1990 Insulin and atheroma 20-yr perspective. Diabetes Care. 13:631-654.
4. Mason B, Oakley N, Wynn V. 1973 Studies of carbohydrate and lipid metabolism in women developing hypertension on oral contraceptives. Br Med J. 3:317-320.
5. Wynn V, Adams PW, Godsland I, et al. 1979 Comparison of effects of different combined oral-contraceptive formulations on carbohydrate and lipid metabolism. Lancet. 1:1045-1049.
6. Kasdorf G, Kalkhoff RK. 1988 Prospective studies of insulin sensitivity in normal women receiving oral contraceptive agents. J Clin Endocrinol Metab. 66:846-852.
7. Buchler D, Warren JC. 1966 Effects of estrogen on glucose tolerance. Am J Obstet Gynecol. 95:479-483.
8. Ajabor LN, Tsai CC, Vela P, Yen SSC. 1972 Effect of exogenous estrogen on carbohydrate metabolism in postmenopausal women. Am J Obstet Gynecol. 113:383-387.
9. Spellacy WN, Buhl WC, Birk SA. 1972 The effect of estrogens on carbohydrate metabolism: glucose, insulin, and growth hormone studies on one hundred and seventy-one women ingesting Prema-rin, mestranol, and ethinyl estradiol for six months. Am J Obstet Gynecol. 114:378-392.
10. De Cleyn K, Buytaert P, Coppens M. 1989 Carbohydrate metabolism during hormonal substitution therapy. Maturitas. 11:235-242.
11. Cagnacci A, Soldani R, Carriero PL, et al. 1992 Effects of low doses of transdermal 17β-estradiol on carbohydrate metabolism in postmenopausal women. J Clin Endocrinol Metab. 74:1396-1400.
12. Barrett-Connor E, Laakso M. 1990 Ischemic heart disease risk in postmenopausal women. Effects of estrogen use on glucose and insulin levels. Arteriosclerosis. 10:531-534.
13. Nabulsi AA, Folsom AR, White A, et al. 1993 Association of hormone-replacement therapy with various cardiovascular risk factors in postmenopausal women. N Engl J Med. 328:1069-1075.
14. Weissberger AJ, Ho KKY, Lazarus L. 1991 Contrasting effects of oral and transdermal routes of estrogen replacement therapy on 24-hour growth hormone (GH) secretion, insulin-like growth factor 1 and GH-binding protein in postmenopausal women. J Clin Endocrinol Metab. 72:374-381.
15. Kelly JJ, Rajkovic IA, O'Sullivan AJ, Semia C, Ho KKY. 1993 Effects of different oral oestrogen formulations on insulin-like growth factor-1, growth hormone and growth hormone binding protein in post-menopausal women. Clin Endocrinol (Oxf). 39: 561-567.
16. Rizza RA, Mandarino LJ, Gerich JE. 1982 Effects of growth hormone on insulin action in man. Mechanisms of insulin resistance, impaired suppression of glucose production and impaired stimulation of glucose utilization. Diabetes. 31:663-669.
17. Powers MS, Schenkel L, Darley PE, et al. 1985 Pharmacokinetics and pharmacodynamics of transdermal dosage forms of 17β-estra-diol: comparison with conventional oral estrogens used for hormone replacement. Am J Obstet Gynecol. 152:1099-1106.
18. Chetkowski RJ, Meldrum DR, Steingold KA, et al. 1986 Biological effects of transdermal estradiol. N Engl J Med. 314:1615-1620.
19. DeFronzo RA, Tobin JD, Andres R. 1979 Glucose clamp techique: a method for quantifying insulin secretion and resistance. Am J Physiol. 237:214-223.
20. Ho KKY, Jenkins AB, Furier SM, Borkman Ms, Chisholm DJ. 1992 Impact of octreotide, a long-acting somatostatin analogue, on glucose tolerance and insulin sensitivity in acromegaly. Clin Endocrinol (OxO. 36:271-279.
21. McGuire EAH, Heldermen JH, Tobin JD, Andres R, Berman M. 1976 Effects of arterial versus venous sampling on analysis of glucose kinetics in man. J Appl Physiol. 41:565-573.
22. Bonadonna RC, Groop L, Kraemer N, et al. 1990 Obesity and insulin resistance in humans: a dose response study. Metabolism. 39: 452-459.
23. Ho KY, Weissberger AJ, Marbach P, Lazarus L. 1990 Therapeutic efficacy of the somatostatin analog 201-995 (octreotide) in acromegaly: effects of dose and frequency and long-term safety. Ann Intern Med. 112:173-181.
24. Kraegen EW, Lazarus L, Campbell LV. 1983 Failure of insulin infusion during euglycemia to influence endogenous basal insulin secretion. Metabolism. 32:622-627.
25. Grizzle JE. 1965 The two-period change-over design and its use in clinical trials. Biometrics. 21:467-480.
26. Dawson-Hughes B, Stem D, Goldman J, Reichlin S. 1986 Regulation of growth hormone and somatomedin-C secretion in postmenopausal women: effect of physiological estrogen replacement. J Clin Endocrinol Metab. 63:424-432.
27. Godsland IF, Ganger K, Walton C, et al. 1993 Insulin resistance, secretion, and elimination in postmenopausal women receiving oral and transdermal hormone replacement therapy. Metabolism. 42: 846-853.
28. Bratusch-Marrain PR, Gasic S, Waldhausl WK, Nowotny P. 1984 The effect of growth hormone on splanchnic glucose and substrate metabolism following oral glucose loading in healthy man. Diabetes. 33:19-25.
29. Herington AC, Ymer S, Stevenson J. 1986 Identification and characterization of specific binding proteins for growth hormone in normal sera. J Clin Invest. 77:1817-1823.
30. Ho KKY, Valiontis E, Waters MJ, Rajkovic IA. 1993 Regulation of growth hormone binding protein in man: comparison of gel chromatography and immunoprécipitation methods. J Clin Endocrinol Metab. 76:302-308.
31. Lim L, Spencer SA, Mckay P, Waters MJ. 1990 Regulation of growth hormone (GH) bioactivity by a recombinant human GH-binding protein. Endocrinology. 127:1287-1291.
32. Luotola H, Pyorala T, Loikkanen M. 1986 Effects of natural oestrogen/progestogen substitution therapy on carbohydrate and lipid metabolism in post-menopausal women. Maturitas. 8:245-253.
33. Godsland IF, Walton C, Whitehead M, Wynn V, Stevenson JC. 1991 Effects of transdermal and oral oestrogen and progestin combined hormone replacement therapy on carbohydrate metabolism [Abstract]. J Endocrinol. 129:94.
34. Petitti DB, Perlman JA, Sidney S. 1986 Postmenopausal estrogen use and heart disease. N Engl J Med. 315:131-132.
35. Barrett-Connor E. 1991 Postmenopausal estrogen and prevention bias. Ann Intern Med. 115:455-456.
36. Goldman L, Tosteson ANA. 1991 Uncertainty about postmenopausal estrogen. N Engl J Med. 325:800-802.